On Monday, Shares of California Resources Corp (NYSE:CRC), gained 1.24% to $4.07.
California Resources Corporation declared that its Board of Directors has approved a quarterly dividend of 1 cent per share, payable October 15, 2015 to stockholders of record at the close of business on September 10, 2015. The current annualized rate would be $0.04 per share
California Resources Corporation operates as an oil and natural gas exploration and production company in the State of California. It produces oil, natural gas, and natural gas liquids.
Shares of Juno Therapeutics Inc (NASDAQ:JUNO), inclined 0.77% to $44.32, during its last trading session.
Juno Therapeutics, declared that the Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act), as amended, in connection with the global partnership agreement executed by the company on June 29, 2015 with Celgene for the development and commercialization of immunotherapies.
With the early termination of the applicable waiting period under the HSR Act, the global partnership agreement with Celgene became effective on July 31, 2015. Celgene will make an initial payment of about $1 billion, composed of an about $150 million upfront payment and about $849.8 million to purchase 9,137,672 shares of Juno’s common stock at $93.00 per share. The sale of shares was made following the terms of the Share Purchase Agreement reached June 29, 2015, by and among Juno, Celgene Corporation, and Celgene RIVOT Ltd., as formerly stated by Juno.
Juno Therapeutics, Inc., a biopharmaceutical company, engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.
Finally, Incyte Corporation (NASDAQ:INCY), ended its last trade with 1.90% gain, and closed at $103.94.
Incyte Corporation, stated 2015 second-quarter financial results, counting revenue from Jakafi.
The Company highlighted the continued momentum in the commercialization of Jakafi in the U.S., in addition to progress being made across its clinical portfolio, counting the results of two pivotal trials of baricitinib that were presented with Eli Lilly and Company (“Lilly”) at the 2015 European League Against Rheumatism (EULAR) meeting in June. In addition, positive proof-of-concept results from the novel:novel combination of Incyte’s PI3Kδ inhibitor INCB40093 and JAK1-selective inhibitor INCB39110 in B-cell malignancies were presented at both the 2015 American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings in the second quarter of 2015.
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics primarily for oncology. It offers JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), counting primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
